Menu
Search
|

Menu

Close
X

Cyclacel Pharmaceuticals Inc CYCC.OQ (NASDAQ Stock Exchange Capital Market)

1.40 USD
+0.02 (+1.45%)
As of 2:54 PM EDT
chart
Previous Close 1.38
Open 1.38
Volume 2,683
3m Avg Volume 12,530
Today’s High 1.41
Today’s Low 1.38
52 Week High 2.25
52 Week Low 1.29
Shares Outstanding (mil) 12.00
Market Capitalization (mil) 16.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
1
FY15
2
EPS (USD)
FY18
-0.275
FY17
-1.962
FY16
-3.588
FY15
-6.218
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
--
6.55
Price to Book (MRQ)
vs sector
0.90
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-45.44
12.83
Return on Equity (TTM)
vs sector
-94.54
14.95

EXECUTIVE LEADERSHIP

David U'Prichard
Independent Chairman of the Board, Since 2006
Salary: --
Bonus: --
Spiro Rombotis
President, Chief Executive Officer, Director, Since 2006
Salary: $530,553.00
Bonus: $185,694.00
Christopher Henney
Independent Vice Chairman of the Board, Since 2009
Salary: --
Bonus: --
Paul McBarron
Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director, Since 2009
Salary: $319,283.00
Bonus: $111,749.00
Judy Chiao
Vice President - Clinical Development and Regulatory Affairs, Since 2006
Salary: $348,379.00
Bonus: $97,546.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Connell Dr Ste 1500
BERKELEY HEIGHTS   NJ   07922-2811

Phone: +1908.5177330

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

SPONSORED STORIES